CIK 0001730430 · Large accelerated filer
Kiniksa Pharmaceuticals International, plc
Sign in to watch- Ticker
- KNSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981795578
- Phone
- 7814319100
- Business address
- 105 PICCADILLY, SECOND FLOOR, LONDON, United Kingdom, W1J 7NJ
- Former names
- Kiniksa Pharmaceuticals, Ltd.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $78,588,440
- in 8 filings, $78.6M under 10b5-1 plans
Net −$78,588,440. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Patel Sanj K −$51.7M CHAIRMAN & CEO sold 42% of stake
- Moat Ross −$9.6M CHIEF OPERATING OFFICER sold 91% of stake
- Paolini John F. −$8.9M CHIEF MEDICAL OFFICER sold 58% of stake
- Megna Michael R −$4.9M CHIEF ACCOUNTING OFFICER sold 80% of stake
- Ragosa Mark −$3.4M CHIEF FINANCIAL OFFICER sold 64% of stake
Reading 59 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-07 | Megna Michael R CHIEF ACCOUNTING OFFICER | Option exercise · Restricted Share Unit | −3,932 | 0 | ||
| 2026-04-06 | Moat Ross CHIEF OPERATING OFFICER | Sale 10b5-1 | −2,367 | $48.58 | $115K | 12,029 |
| 2026-04-06 | Patel Sanj K CHAIRMAN & CEO | Option exercise 10b5-1 | +7,278 | $10.36 | $75K | 7,278 |
| 2026-04-06 | Patel Sanj K CHAIRMAN & CEO | Sale 10b5-1 | −7,278 | $50.01 | $364K | 0 |
| 2026-04-06 | Patel Sanj K CHAIRMAN & CEO | Option exercise · Share Option 10b5-1 | −7,278 | 431,904 | ||
| 2026-04-06 | Quart Barry D Director | Option exercise 10b5-1 | +6,901 | $14.33 | $99K | 19,447 |
| 2026-04-06 | Quart Barry D Director | Sale 10b5-1 | −6,901 | $50.00 | $345K | 12,546 |
| 2026-04-06 | Quart Barry D Director | Option exercise · Share Option 10b5-1 | −6,901 | 26,336 | ||
| 2026-04-01 | Tessari Eben CHIEF STRATEGY OFFICER | Option exercise | +5,975 | 23,006 | ||
| 2026-04-01 | Tessari Eben CHIEF STRATEGY OFFICER | Shares withheld for taxes | −1,756 | $48.13 | $85K | 21,250 |
| 2026-04-01 | Tessari Eben CHIEF STRATEGY OFFICER | Grant or award · Share Option | +33,200 | 33,200 | ||
| 2026-04-01 | Tessari Eben CHIEF STRATEGY OFFICER | Grant or award · Restricted Share Unit | +8,300 | 8,300 | ||
| 2026-04-01 | Tessari Eben CHIEF STRATEGY OFFICER | Grant or award · Performance Share Unit | +16,600 | 16,600 | ||
| 2026-04-01 | Tessari Eben CHIEF STRATEGY OFFICER | Option exercise · Restricted Share Unit | −1,773 | 1,772 | ||
| 2026-04-01 | Tessari Eben CHIEF STRATEGY OFFICER | Option exercise · Restricted Share Unit | −1,745 | 3,490 | ||
| 2026-04-01 | Tessari Eben CHIEF STRATEGY OFFICER | Option exercise · Restricted Share Unit | −2,457 | 7,371 | ||
| 2026-04-01 | Moat Ross CHIEF OPERATING OFFICER | Option exercise | +5,808 | 16,102 | ||
| 2026-04-01 | Moat Ross CHIEF OPERATING OFFICER | Shares withheld for taxes | −1,706 | $48.13 | $82K | 14,396 |
| 2026-04-01 | Moat Ross CHIEF OPERATING OFFICER | Grant or award · Share Option | +36,950 | 36,950 | ||
| 2026-04-01 | Moat Ross CHIEF OPERATING OFFICER | Grant or award · Restricted Share Unit | +9,250 | 9,250 |
Page 14 of 74 · 1,467 trades